This study, called TRIDENT, is looking at how a specific type of talk therapy, Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD), affects depression, the immune system, and brain function in people living with HIV. Researchers want to understand how CBT-AD changes the gut microbiome (the tiny organisms in your gut), immune system, and brain activity. You might be able to join if you are 18 or older, speak English, have HIV-1 infection and are on antiretroviral therapy (ART), and have a current diagnosis of Major Depressive Disorder. The study aims to see if changes in brain activity related to negative emotions improve after receiving CBT-AD. The current recruitment status is unclear, and 150 people are planned to enroll.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It is a randomized controlled trial, but the phase is not specified.

What's involved

Participants will receive up to 12 individual CBT-AD sessions over 4 months, each lasting about 50 minutes. There will also be up to three booster sessions through 6 months, and a single session of Antiretroviral Therapy (ART) Adherence Counseling.

Compensation

Not stated in the trial record.

Follow-up

The study measures changes in brain activity at 6 months, suggesting follow-up for at least that long after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.